• Adenovirus Service • AAV Service • Lentivirus Service • Retrovirus Service
Transplantation of gene-edited autologous hematopoietic stem cells has been shown to be a curative treatment for hematopoietic disorders, including β-thalassemia and sickle cell disease (SCD). While this approach has been successful in numerous clinical trials, eliminates the need for donor matching, and potentially prevents graft-versus-host disease (GvHD), it remains hampered by the difficulty in obtaining sufficient high-quality hematopoietic stem cells for ex vivo manipulation. Furthermore, prior to transplantation, myeloablative conditioning (typically chemotherapy) is required to eliminate the patient's own hematopoietic stem cells to create space in the bone marrow microenvironment for the gene-edited autologous hematopoietic stem cells. The complex process, high production costs, and significant side effects have severely limited clinical application and commercialization.
Acute pancreatitis (AP) is associated with high mortality and is characterized by increased acinar cell death and premature release and activation of digestive enzymes. During the acute phase, AP is accompanied by enhanced efferocytosis to clear apoptotic cells. The Anxa1 protein is crucial for efferocytosis, but its role in AP remains unclear. Recently, researchers published a study titled "Annexin A1 mRNA-loaded liposomes alleviate acute pancreatitis by suppressing the STING pathway and promoting efferocytosis in macrophages" in Nature Nanotechnology.
In recent years, scientists have made significant progress in cancer treatment, particularly in the development of inhibitors targeting the MYC gene. The MYC gene plays a key role in many aggressive cancers, with its aberrant activation closely linked to tumor growth and treatment resistance. Approximately 30% of cancer patients have abnormal MYC expression, making MYC a key target for cancer treatment. However, due to its complex structure and function, MYC has long been considered an undruggable target. Technological advances have enabled several MYC inhibitors to enter clinical trials, but their efficacy still requires further improvement. Therefore, exploring combination therapy strategies that synergize with MYC inhibitors is poised to become a hot topic in cancer research.
In recent years, scientists have gradually discovered that the development and progression of many cancers are closely linked to mutations in specific genes. Among them, abnormalities in the KRAS and MYC genes, like a cancer duo, play a key role in many cancers. Now, scientists from the University of North Carolina and other institutions have achieved a significant breakthrough. They have developed a two-in-one molecule that simultaneously targets and silences both cancer-related genes, KRAS and MYC, and precisely delivers the drug directly to tumor cells expressing these genes. This discovery not only offers new hope for treating some difficult-to-treat cancers but also provides new insights into cancer treatment.
Recently, a research team led by Aaron M. Ring of the Fred Hutchinson Cancer Research Center, Harriet M. Kluger of the Yale University School of Medicine, and Leon Furchtgott of the biotechnology company Seranova Bio published a major study in the top journal Nature.
CAR-T cell therapy has revolutionized the treatment of B-cell malignancies and is now showing initial success in solid tumors. Despite continued progress, many patients treated with CAR therapy fail to respond or develop resistance. This highlights the urgent need to further optimize current treatment options.
Long noncoding RNAs (lncRNAs) make up a significant portion of the genome and encompass a diverse class of RNA molecules that are not translated into proteins. As important regulators of cell and tissue function, lncRNAs have been shown to be closely associated with the development and progression of metabolic diseases. Type 2 diabetes is a metabolic disease that poses an increasing burden on public health. The etiology of type 2 diabetes is complex, involving multiple tissues leading to glucose homeostasis disorders.
The immunogenicity of lipid nanoparticles (LNPs) used to deliver nucleoside-modified mRNA limits the expression level and duration of proteins encoded by mRNA, which is not conducive to the therapeutic effect of LNP-mRNA therapy.
The emergence of immune checkpoint blockade (ICB) therapy has brought revolutionary changes to cancer treatment. By using antibodies to block the "deceptive signals" sent by cancer cells using immune checkpoints, immune checkpoint blockade therapy can activate the host's immune system to attack cancer cells, thus bringing new hope for treatment for patients with various cancers. However, a thorny question has always troubled scientists, that is, why do some tumors become resistant to immune checkpoint blockade therapy?
Adeno-associated virus (AAV) is currently the most commonly used in vivo gene therapy vector and has been approved for the treatment of a variety of diseases including retinitis pigmentosa, spinal muscular atrophy, Duchenne muscular dystrophy and hemophilia.
